Ask AI
ProCE Banner Events

Share

Conversations in Advanced RCC: Guidance on Immunotherapy and Immunotherapy-Based Combinations

Join us for this online, live engaging roundtable webinar as expert faculty discuss current guidance and emerging strategies for treating patients with advanced RCC. Practical information on treatment selection and management of patients receiving therapy for RCC will be reviewed as the experts consider patient case examples. Sign up today!

To Register:  Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation. 

maximum of 1.00 AMA PRA Category 1 Credit

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for urologic and medical oncologists, urologists, and other multidisciplinary care team members who treat patients with advanced/metastatic RCC.

Time and location

Monday, June 05, 2023

6:30 AM - 7:30 AM Central Time (CT)

Virtual

Agenda

  • Discussion: Impact of Adjuvant Therapy on Subsequent Lines of Therapy
  • Discussion: Immunotherapy and Immunotherapy-Based Combinations in the Frontline Setting 
  • Discussion: Immunotherapy and Immunotherapy-Based Combinations for Relapsed/Refractory RCC
  • Discussion: Experimental Approaches and the Clinical Trial Landscape with Subsequent Therapy Lines

CME/CE Info

Goal Statement
This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance, practice-changing data, and expert recommendations on immunotherapy and immunotherapy-based combinations in advanced/metastatic RCC.

Target Audience
This program is intended for urologic and medical oncologists, urologists, and other multidisciplinary care team members who treat patients with advanced/metastatic RCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Formulate treatment plans in the frontline setting using available clinical evidence and patient-, disease-, and treatment-related factors in patients with advanced/metastatic RCC
  • Appraise clinical trial data evaluating the use of anti‒PD-1/PD-L1 antibody/multikinase inhibitor and anti‒PD-1/anti‒CTLA-4/multikinase inhibitor combination therapy in patients with advanced/metastatic RCC
  • Review expert-recommended therapeutic sequencing of systemic therapies for patients with advanced/metastatic RCC that has progressed on first-line treatment, incorporating immunotherapeutic agents and other therapeutic strategies
  • Integrate best practices to recognize, mitigate, and manage the unique suite of adverse events associated with immunotherapy and immunotherapy-based combination treatment approaches for patients with advanced/metastatic RCC  

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Bristol Myers Squibb.

Contact Information

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.